Veliparib is a small-molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed by AbbVie. PARP is an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events.
Vascepa (icosapent ethyl) is marketed by Amarin for the treatment of severe hypertriglyceridemia. The molecule itself is a semi-synthetic, highly purified derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA).
Waylivra (volanesorsen; Ionis Pharmaceuticals) is an antisense drug that inhibits the translation and production of ApoC-III.
VK2809 (Viking Therapeutics) is a thyroid hormone receptor (THR) β-selective agonist which is selective to liver tissue. It is delivered as a prodrug. VK2809 selectively activates the cytochrome P450 isozyme 3A4 (CYP3A4), which is predominantly found in the liver. This allows increased hepatic exposure, which simultaneously reduces systemic exposure to other tissues such as skeletal muscle and the heart.
Zulresso is SAGE Therapeutics’ proprietary intravenous formulation of brexanolone, which is an allosteric modulator of both synaptic and extra-synaptic GABA-A receptors.
Viibryd (vilazodone; Allergan) belongs to a new class of antidepressants, combining selective serotonin reuptake inhibitor activity with partial 5-HT1A receptor agonism, in order to produce its therapeutic effect.
Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical studies have shown the role of PDGF in modulating angiogenesis
Venclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins.
Zanubrutinib (BeiGene) is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK), developed to be more selective with less off-target effects than Imbruvica (ibrutinib; AbbVie/Johnson & Johnson). BTK is part of the B-cell receptor signaling pathway, which promotes cell proliferation, adhesion, and survival in many B-cell malignancies.
Zydelig (idelalisib; Gilead) is an oral, highly selective inhibitor of the phosphoinositide 3-kinase (PI3K) isoform p110-delta. In vitro studies have demonstrated that Zydelig results in decreased phosphorylation Akt and other downstream effectors, an increase in poly (ADP-ribose) polymerase and caspase cleavage, and an induction of apoptosis.
Ublituximab (TG Therapeutics) is an anti-CD20 monoclonal antibody, currently in late-stage trials across a range of hematological and neurological indications.
Zevalin (ibritumomab tiuxetan; Acrotech Biopharma/Mundipharma) is an intravenous radioactive agent consisting of the murine monoclonal antibody (MAb) ibritumomab, which is covalently linked to the chelator tiuxetan.
Yescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained US approval for relapsed/refractory patients in October 2017.
Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU.
Uptravi (selexipag; Nippon Shinyaku/Actelion) is the first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!